Document is current
Any future updates will be listed below
-
Authors
Sahoo, Ashutosh https://orcid.org/0000-0003-0879-6683
Mohapatra, Amit Kumar
Priyadarsini, Haripriya
Pemmadi, Raghuveer Varma
Das, Anjan
Choedon, Tenzin
Nikam, Chaitali
Behera, Rajendra Kumar
Masakapalli, Shyam Kumar https://orcid.org/0000-0003-1988-5569
Nanda, Ranjan Kumar
-
Funding
Funding for this research was provided by:
Department of Biotechnology, Ministry of Science and Technology, India (BT/PR23238/NER/95/636/2017)
- License Information
-
More Information
Article History
Received: 10 May 2025
Accepted: 6 December 2025
First Online: 27 December 2025
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose.
: Not applicable.
: This study was approved by the human ethics committees of the Agartala Government Medical College, Agartala (F.4 [ – ]/AGMC/Academic/IEC Committee/2015/8965, dated 25 April 2018) and International Centre for Genetic Engineering and Biotechnology, New Delhi (ICGEB/IEC/2017/07). Subjects or patients with symptoms of tuberculosis disease like cough for 2 weeks or more, weight loss, fever, and night sweats reporting to the outpatient department of the hospital were recruited after receiving their signed informed consent forms by the individual or their concerned guardian. Sputum samples (day 0 and day 1) of these subjects were taken for sputum microscopy at the hospital and culture test for drug sensitivity test using Mycobacteria Growth Indicator Tube (MGIT) in BACTEC MGIT 960 System at a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratory following WHO guidelines. All the methods and experimental procedure related with clinical samples was carried out in accordance with ethical guidelines and regulations.
